IN BRIEF: Malin intrinsic equity value falls in half-year

Malin Corp PLC - Dublin-based investor in life sciences companies - Reports intrinsic equity ...

Alliance News 27 August, 2024 | 6:02PM
Email Form Facebook Twitter LinkedIn RSS

Malin Corp PLC - Dublin-based investor in life sciences companies - Reports intrinsic equity value of EUR6.44 at June 30 half-year end, down 1.8% from EUR6.56 at end of December. Declines further to EUR6.33 as at August 22. Attributes decline to lower Poseida share price and a downward revision of its interest in Viamet. Says further studies by Viament on Vivjoa have delayed commercial launches and associated royalties as Viament seeks to receive extended approval for Vivjoa. "We expect further clarity on the future regulatory, commercial and strategic pathway in the months ahead," Malin says. Further, cash position at August 22 increases to EUR62.9 million, from EUR35.7 million at end of June, owing to its divestment of CG Oncology, company says. Divestment generated cash proceeds of about EUR28.5 million, a 175% gain on total capital invested.

Current share price: EUR5.90

12-month change: up 28%

By Aidan Lane, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Malin Corporation PLC 5.90 EUR -9.23 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures